RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan
Principal Investigator
Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy (MM-398-01-03-04), NCT03088813
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy
The study will be conducted in two parts:
- Dose determination of irinotecan liposome injection
- A randomized, efficacy study of irinotecan liposome injection versus topotecan
MORE DETAILS ON THIS TRIAL
17099 / NCT03088813 / Call PM / Open 11-13-2018
TRIAL AVAILABLE AT THESE LOCATIONS:
